Abstract: A birefringent film comprising at least one birefringent layer of liquid crystal material forming multi domains with a splayed structure may be coated onto a reflective substrate, e.g., with an aluminium surface. The birefringent film is particularly suited for decorative, security, authentification or identification applications.

Abstract: The present invention relates to novel pharmaceutical tablets useful for administering pharmaceutical active ingredients, such as bisphosphonates. These tablets have improved surface properties which can aid esophageal transit, thereby reducing the potential for adverse gesture intestinal effects. The present invention also relates to processes for making said novel pharmaceutical tablets.

Abstract: A system tot the pulsation-free delivery of liquids, which system may be used for high-purity, liquid chemicals in the semiconductor industry.

Abstract: An automated packaging line has capability of filling large and small orders, of one or more bottles, each bottle filled with a respective one of a plurality of different pharmaceutical tablets, in a single run. Structure is provided for filling orders for an individual consumer, for a pharmacist, and for a wholesaler, simultaneously, using differently sized bottles, and providing customized labels for each bottle. A flexible filler station simultaneously fills plural bottles with respective tablets. An intelligent data carrying puck carries each bottle, including therein information describing, among others, the bottle, the customer, the order, the pharmaceutical, the bottle size and label information. Puck handling stations (PHS) are dispersed throughout the line, to verify a number of operations implemented on the line and to reject a puck at the earliest opportunity, while permitting subsequent rejection by a subsequent PHS.

Abstract: The present invention relates to a process for preparing a compound of gonadotropin releasing hormone antagonists having a Formula I, in an efficient way, which involves preparation of key intermediates: 2-arylindole core; a chiral aziridine, in particular chiral nosyl aziridine; and an amine salt. The key process involves the coupling reaction of 2-arylindole and nosyl aziridine under boron trifluoride catalysis, which provides the final compound with unprecedented regioselectivity and enantioselectivity.

Abstract: The invention relates to novel dioxane derivatives of the formula I R1—(A1—Z1)m—A2—C2F4—A3—(Z2—A4)n—R2  I in which R1, R2, A1, A2, A3, A4, Z1, Z2, m and n are as defined herein, to their use as components of liquid-crystalline media, and to liquid-crystal and electro-optical display elements which contain the liquid-crystalline media according to the invention.

Abstract: The present invention relates to the compounds of formula: 1

Abstract: The invention relates to new reactive mesogenic azulene derivatives, their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like for example liquid crystal displays, optical films, organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the reactive mesogenic azulenes.

Abstract: A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by a (cyano)(fluoro)phenyl moiety, being selective ligands for GABAA receptors, in particular having good affinity for the &agr;2 and/or &agr;3 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety and convulsions.

Abstract: The invention relates to a method for removing endotoxins from nucleic acids. The endotoxins are removed by pre-incubating the nucleic acids in a salt-free detergent solution and subsequent anion exchange chromatography on a tentacle anion exchanger.

Abstract: The present invention provides liquid and lyophilized formulations of vaccines against rotavirus infection and methods of their preparation. The formulations include buffering agents appropriate for oral administration of rotavirus vaccines. The formulations also include compounds to stabilize of the vaccine compositions against loss of potency.

Abstract: Human, swine and rat growth hormone secretagogue receptors have been isolated, cloned and sequenced. Growth hormone secretagogue receptors are new members of the G-protein family of receptors. The growth hormone secretagogue receptors may be used to screen and identify compounds which bind to the growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and recovering from hip fracture and osteoporosis.

Abstract: New oxadiazole derivatives comprising one or more identical or different recurring units of formula I 1

Abstract: Liquid-crystalline media comprising one or more compounds of formula A and at least one compound of formula B are suitable for use in TN and STN displays.

Abstract: The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

Abstract: A class of 1,2,3a,4,x-pentaaza-cyclopenta[a]naphthalene compounds (x=6, 7, 8 or 9) is described. The compounds have a high affinity for the GABAA &agr;5 receptors and show inverse agonist activity thereat. The compounds are useful in therapy where cognition enhancement is required.

Abstract: Compounds of the formula I in which R1 denotes CONR4R5, R2 denotes H or A, R4 and R5, independently of one another, each denote H or A1, R3 denotes Hal, Hal denotes F, Cl, Br or I, A denotes alkyl having 1-4 carbon atoms, A1 denotes alkyl having 1-10 carbon atoms, X denotes alkylene having 1-4 carbon atoms, in which an ethylene group may also be replaced by a double or triple bond, and their physiologically acceptable salts and/or solvates, as phosphodiesterase VII inhibitors, and their use for the preparation of a medicament.

Abstract: The invention relates to polymerisable monocyclic compounds, their use in liquid crystal mixtures, polymers and polymer films, and the use of the compounds, mixtures, polymers and polymer films in optical, electrooptical and electronic devices, for decorative and security applications.

Abstract: Liquid crystalline media comprising a dielectrically positive component A, comprising compounds of formula I 1

Abstract: The present invention is directed to peptidomimetic macrocyclic compounds that inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.